LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 5 of total 5

Search options

  1. Article ; Online: Azole resistance surveillance in Aspergillus fumigatus: beneficial or biased?

    Verweij, Paul E / Lestrade, Pieter P A / Melchers, Willem J G / Meis, Jacques F

    The Journal of antimicrobial chemotherapy

    2016  Volume 71, Issue 8, Page(s) 2079–2082

    Abstract: Azole resistance is a growing concern with Aspergillus fumigatus, and may cause increased mortality in patients with azole-resistant invasive aspergillosis (IA). Microbial surveillance has been recognized as a fundamental component of resistance ... ...

    Abstract Azole resistance is a growing concern with Aspergillus fumigatus, and may cause increased mortality in patients with azole-resistant invasive aspergillosis (IA). Microbial surveillance has been recognized as a fundamental component of resistance management. Surveillance information may be used to inform decisions regarding health services and research funding allocation, to guide local infection control in hospitals and communities, and to direct local and national drug policies and guidelines. Azole resistance frequencies have been based on screening of unselected A. fumigatus isolates, on the number of azole-resistant cases within a cohort of patients with a specific Aspergillus disease, or on analysis of patients within a specific risk group. The various surveillance approaches differ in their aims, as well as in their associated advantages and drawbacks. Nevertheless, a wide range of azole resistance frequencies has been reported, partly due to the denominator used. As most azole resistance is believed to develop in the environment and, as a consequence, azole-naive patients may present with azole-resistant aspergillosis, experts recommended a 10% resistance frequency threshold above which the standard treatment choice, i.e. voriconazole, should be reconsidered. We believe that local resistance rates based on Aspergillus disease and/or risk group should be leading for decisions regarding empirical antifungal therapy in specific units. In addition, patient factors should be considered, such as admission to the ICU. Collecting valid surveillance data may be challenging in azole resistance due to numerous factors that present potential biases. Surveillance research may benefit from further standardization, which may be facilitated through the recently instituted International Society for Human and Animal Mycology (ISHAM) Aspergillus Resistance Surveillance Working Group.
    MeSH term(s) Antifungal Agents/pharmacology ; Aspergillosis/drug therapy ; Aspergillosis/epidemiology ; Aspergillosis/microbiology ; Aspergillus fumigatus/drug effects ; Aspergillus fumigatus/isolation & purification ; Azoles/pharmacology ; Drug Resistance, Fungal ; Epidemiological Monitoring ; Humans ; Prevalence
    Chemical Substances Antifungal Agents ; Azoles
    Language English
    Publishing date 2016-08
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 191709-2
    ISSN 1460-2091 ; 0305-7453
    ISSN (online) 1460-2091
    ISSN 0305-7453
    DOI 10.1093/jac/dkw259
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Paradoxal Trends in Azole-Resistant Aspergillus fumigatus in a National Multicenter Surveillance Program, the Netherlands, 2013-2018.

    Lestrade, Pieter P A / Buil, Jochem B / van der Beek, Martha T / Kuijper, Ed J / van Dijk, Karin / Kampinga, Greetje A / Rijnders, Bart J A / Vonk, Alieke G / de Greeff, Sabine C / Schoffelen, Annelot F / van Dissel, Jaap / Meis, Jacques F / Melchers, Willem J G / Verweij, Paul E

    Emerging infectious diseases

    2020  Volume 26, Issue 7, Page(s) 1447–1455

    Abstract: We investigated the prevalence of azole resistance of Aspergillus fumigatus isolates in the Netherlands by screening clinical A. fumigatus isolates for azole resistance during 2013-2018. We analyzed azole-resistant isolates phenotypically by in vitro ... ...

    Abstract We investigated the prevalence of azole resistance of Aspergillus fumigatus isolates in the Netherlands by screening clinical A. fumigatus isolates for azole resistance during 2013-2018. We analyzed azole-resistant isolates phenotypically by in vitro susceptibility testing and for the presence of resistance mutations in the Cyp51A gene. Over the 6-year period, 508 (11%) of 4,496 culture-positive patients harbored an azole-resistant isolate. Resistance frequency increased from 7.6% (95% CI 5.9%-9.8%) in 2013 (58/760 patients) to 14.7% (95% CI 12.3%-17.4%) in 2018 (112/764 patients) (p = 0.0001). TR
    MeSH term(s) Antifungal Agents/pharmacology ; Antifungal Agents/therapeutic use ; Aspergillus fumigatus/genetics ; Azoles/pharmacology ; Drug Resistance, Fungal ; Fungal Proteins/genetics ; Humans ; Microbial Sensitivity Tests ; Netherlands/epidemiology
    Chemical Substances Antifungal Agents ; Azoles ; Fungal Proteins
    Language English
    Publishing date 2020-06-20
    Publishing country United States
    Document type Journal Article ; Multicenter Study
    ZDB-ID 1380686-5
    ISSN 1080-6059 ; 1080-6040
    ISSN (online) 1080-6059
    ISSN 1080-6040
    DOI 10.3201/eid2607.200088
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients.

    Resendiz-Sharpe, Agustin / Mercier, Toine / Lestrade, Pieter P A / van der Beek, Martha T / von dem Borne, Peter A / Cornelissen, Jan J / De Kort, Elizabeth / Rijnders, Bart J A / Schauwvlieghe, Alexander F A D / Verweij, Paul E / Maertens, Johan / Lagrou, Katrien

    The Journal of antimicrobial chemotherapy

    2019  Volume 74, Issue 9, Page(s) 2759–2766

    Abstract: Background: Increasing resistance of Aspergillus fumigatus to triazoles in high-risk populations is a concern. Its impact on mortality is not well understood, but rates from 50% to 100% have been reported.: Objectives: To determine the prevalence of ... ...

    Abstract Background: Increasing resistance of Aspergillus fumigatus to triazoles in high-risk populations is a concern. Its impact on mortality is not well understood, but rates from 50% to 100% have been reported.
    Objectives: To determine the prevalence of voriconazole-resistant A. fumigatus invasive aspergillosis (IA) and its associated mortality in a large multicentre cohort of haematology patients with culture-positive IA.
    Methods: We performed a multicentre retrospective study, in which outcomes of culture-positive haematology patients with proven/probable IA were analysed. Patients were stratified based on the voriconazole susceptibility of their isolates (EUCAST broth microdilution test). Mycological and clinical data were compared, along with survival at 6 and 12 weeks.
    Results: We identified 129 A. fumigatus culture-positive proven or probable IA cases; 103 were voriconazole susceptible (79.8%) and 26 were voriconazole resistant (20.2%). All but one resistant case harboured environment-associated resistance mutations in the cyp51A gene: TR34/L98H (13 cases) and TR46/Y121F/T289A (12 cases). Triazole monotherapy was started in 75.0% (97/129) of patients. Mortality at 6 and 12 weeks was higher in voriconazole-resistant cases in all patients (42.3% versus 28.2%, P = 0.20; and 57.7% versus 36.9%, P = 0.064) and in non-ICU patients (36.4% versus 21.6%, P = 0.16; and 54.4% versus 30.7%; P = 0.035), compared with susceptible ones. ICU patient mortality at 6 and 12 weeks was very high regardless of triazole susceptibility (75.0% versus 66.7%, P = 0.99; and 75.0% versus 73.3%, P = 0.99).
    Conclusions: A very high prevalence of voriconazole resistance among culture-positive IA haematology patients was observed. The overall mortality at 12 weeks was significantly higher in non-ICU patients with voriconazole-resistant IA compared with voriconazole-susceptible IA.
    MeSH term(s) Aged ; Antifungal Agents/pharmacology ; Antifungal Agents/therapeutic use ; Aspergillosis/drug therapy ; Aspergillosis/epidemiology ; Aspergillosis/etiology ; Aspergillosis/mortality ; Aspergillus fumigatus/drug effects ; Aspergillus fumigatus/genetics ; Cytochrome P-450 Enzyme System/genetics ; Drug Resistance, Fungal ; Drug Therapy, Combination ; Female ; Fungal Proteins/genetics ; Hematologic Neoplasms/complications ; Hematologic Neoplasms/epidemiology ; Humans ; Invasive Fungal Infections/drug therapy ; Invasive Fungal Infections/epidemiology ; Invasive Fungal Infections/etiology ; Invasive Fungal Infections/mortality ; Male ; Microbial Sensitivity Tests ; Middle Aged ; Mortality ; Mutation ; Prevalence ; Prognosis ; Retrospective Studies ; Survival Analysis ; Voriconazole/pharmacology ; Voriconazole/therapeutic use
    Chemical Substances Antifungal Agents ; Fungal Proteins ; Cytochrome P-450 Enzyme System (9035-51-2) ; cytochrome P-450 CYP51A, Aspergillus (EC 1.14.14.-) ; Voriconazole (JFU09I87TR)
    Language English
    Publishing date 2019-06-21
    Publishing country England
    Document type Journal Article ; Multicenter Study
    ZDB-ID 191709-2
    ISSN 1460-2091 ; 0305-7453
    ISSN (online) 1460-2091
    ISSN 0305-7453
    DOI 10.1093/jac/dkz258
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Influenza-Associated Aspergillosis in Critically Ill Patients.

    van de Veerdonk, Frank L / Kolwijck, Eva / Lestrade, Pieter P A / Hodiamont, Caspar J / Rijnders, Bart J A / van Paassen, Judith / Haas, Pieter-Jan / Oliveira Dos Santos, Claudy / Kampinga, Greetje A / Bergmans, Dennis C J J / van Dijk, Karin / de Haan, Anton F J / van Dissel, Jaap / van der Hoeven, Hans G / Verweij, Paul E

    American journal of respiratory and critical care medicine

    2017  Volume 196, Issue 4, Page(s) 524–527

    Language English
    Publishing date 2017-04-07
    Publishing country United States
    Document type Journal Article
    ZDB-ID 1180953-x
    ISSN 1535-4970 ; 0003-0805 ; 1073-449X
    ISSN (online) 1535-4970
    ISSN 0003-0805 ; 1073-449X
    DOI 10.1164/rccm.201612-2540LE
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Diagnosis and management of aspergillosis in the Netherlands: a national survey.

    Lestrade, Pieter P A / Meis, Jacques F / Arends, Jan P / van der Beek, Martha T / de Brauwer, Els / van Dijk, Karin / de Greeff, Sabine C / Haas, Pieter-Jan / Hodiamont, Caspar J / Kuijper, Ed J / Leenstra, Tjalling / Muller, Anouk E / Oude Lashof, Astrid M L / Rijnders, Bart J / Roelofsen, Eveline / Rozemeijer, Wouter / Tersmette, Mathijs / Terveer, Elizabeth M / Verduin, Cees M /
    Wolfhagen, Maurice J H M / Melchers, Willem J G / Verweij, Paul E

    Mycoses

    2016  Volume 59, Issue 2, Page(s) 101–107

    Abstract: A survey of diagnosis and treatment of invasive aspergillosis was conducted in eight University Medical Centers (UMCs) and eight non-academic teaching hospitals in the Netherlands. Against a background of emerging azole resistance in Aspergillus ... ...

    Abstract A survey of diagnosis and treatment of invasive aspergillosis was conducted in eight University Medical Centers (UMCs) and eight non-academic teaching hospitals in the Netherlands. Against a background of emerging azole resistance in Aspergillus fumigatus routine resistance screening of clinical isolates was performed primarily in the UMCs. Azole resistance rates at the hospital level varied between 5% and 10%, although rates up to 30% were reported in high-risk wards. Voriconazole remained first choice for invasive aspergillosis in 13 out of 16 hospitals. In documented azole resistance 14 out of 16 centres treated patients with liposomal amphotericin B.
    MeSH term(s) Amphotericin B/therapeutic use ; Antifungal Agents/therapeutic use ; Aspergillosis/diagnosis ; Aspergillosis/drug therapy ; Aspergillosis/epidemiology ; Aspergillus fumigatus/drug effects ; Aspergillus fumigatus/isolation & purification ; Drug Resistance, Fungal ; Humans ; Netherlands/epidemiology ; Surveys and Questionnaires ; Voriconazole/pharmacology ; Voriconazole/therapeutic use
    Chemical Substances Antifungal Agents ; liposomal amphotericin B ; Amphotericin B (7XU7A7DROE) ; Voriconazole (JFU09I87TR)
    Language English
    Publishing date 2016-02
    Publishing country Germany
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 392487-7
    ISSN 1439-0507 ; 0933-7407
    ISSN (online) 1439-0507
    ISSN 0933-7407
    DOI 10.1111/myc.12440
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top